secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-06-16T10:30:49+00:00
Accession:  0001140361-26-025324
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics stockholders elect directors, approve executive pay, auditor, and Series B conversion
--------------------------------------------------------------------------------

- Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. re-elected with ~70.2M and ~70.5M votes for, respectively.
- Non-binding advisory vote on executive compensation approved with 70.5M votes for, 34,907 against.
- Ratification of Grant Thornton Zhitong as independent auditor for FY2026 approved with 72.5M votes for.
- Approval of conversion of Series B Convertible Preferred Stock into common stock passed with 70.5M votes for.
- Broker non-votes reported for all proposals except auditor ratification (none).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/ef20076059_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-025324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer